D
David L. Longworth
Researcher at Cleveland Clinic
Publications - 100
Citations - 4313
David L. Longworth is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Transplantation & Endocarditis. The author has an hindex of 36, co-authored 100 publications receiving 4153 citations. Previous affiliations of David L. Longworth include Beth Israel Deaconess Medical Center & Ohio State University.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of infections involving implantable electrophysiologic cardiac devices.
TL;DR: The Cleveland Clinic Foundation in Ohio has been a referral center for treatment of device-related infections because of the tools and techniques used there to extract leads for transvenous pacemakers and implantable cardioverter defibrillators and to define optimal management of these infections, the recent experience at the Foundation was examined.
Journal ArticleDOI
Lactobacillus Bacteremia and Endocarditis: Review of 45 Cases
TL;DR: Patients with clinically significant lactobacillus bacteremia identifies patients with serious and rapidly fatal illness, many of whom have received prior antibiotic therapy that may select out for the organism.
Journal ArticleDOI
The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants.
A. Minari,Rola N. Husni,Robin K. Avery,David L. Longworth,Malcolm M. DeCamp,M. Bertin,Robert Schilz,N. Smedira,Marcus T. Haug,Atul C. Mehta,Steven M. Gordon +10 more
TL;DR: The highest incidence and attack rate of invasive aspergillosis among solid organ transplant recipients occurs in lung transplant recipients and supports the routine use of Aspergillus prophylaxis for at least one year after transplantation in this group.
Journal ArticleDOI
Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals.
TL;DR: Resistance to most relevant antimicrobials was commonplace among the Gram-negative bacilli; however, most remained susceptible to imipenem, calling for a nationwide surveillance programme to monitor microbial trends and antimicrobial resistance patterns in Egypt.
Journal ArticleDOI
Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients.
Rola N. Husni,Steven M. Gordon,David L. Longworth,Alejandro C. Arroliga,Paul C. Stillwell,Robin K. Avery,Janet R. Maurer,Atul C. Mehta,Thomas J. Kirby +8 more
TL;DR: Optimal strategies to prevent IA in lung transplant recipients remain to be determined, but prevention of aspergillus airway colonization and CMV viremia and disease after transplantation may be important targets for prophylactic interventions.